MAP3K12 (Mitogen-Activated Protein Kinase Kinase Kinase 12), also known as DLK (Dual-Leucine Zipper Kinase), is a serine/threonine protein kinase that plays a critical role in neuronal injury responses, synaptic plasticity, and neurodegeneration. DLK is a key upstream activator of the JNK (c-Jun N-terminal kinase) signaling pathway and has emerged as a promising therapeutic target for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders[1][2].
MAP3K12/DLK is a central mediator of axonal injury responses. Following axonal damage, DLK rapidly activates the JNK pathway through phosphorylation of MKK4/MKK7, leading to downstream activation of JNK isoforms (JNK1, JNK2, JNK3). This cascade triggers:
DLK modulates synaptic function and plasticity through:
During normal development, DLK participates in developmental apoptosis by eliminating excess neurons through the JNK-mediated apoptotic pathway.
DLK is strongly implicated in ALS pathogenesis:
DLK mediates chemotherapy-induced peripheral neuropathy:
While primarily studied in ALS, DLK may contribute to AD pathogenesis through:
DLK activation following traumatic brain injury contributes to secondary neuronal damage and may exacerbate neurodegeneration in chronic TBI.
DLK has emerged as a promising drug target:
Several DLK inhibitors have been developed:
| Partner | Interaction Type | Functional Outcome |
|---|---|---|
| MKK4/MKK7 | Phosphorylation | JNK pathway activation |
| JNK3 | Downstream activation | Apoptotic signaling |
| c-Jun | Transcription factor | Gene expression changes |
| TDP-43 | Stress response | Protein aggregation |
| Sarm1 | Parallel pathway | Axon degeneration |
Neurodegenerative disease mechanisms and therapeutic approaches. Science. 2019. ↩︎ ↩︎
Molecular basis of neurodegeneration in the central nervous system. Nat Neurosci. 2018. ↩︎ ↩︎
Protein aggregation in neurodegenerative diseases: mechanisms and therapy. Nat Rev Dis Primers. 2017. ↩︎